Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.

Denison J. Kuruvilla,Yen Lin Chia,Linda Santiago,Kemal Balic,Nai-Shun Yao,Robert J. Kreitman,Ira Pastan,Xia Li,Meina Liang,Chih-Ming Tseng,Raffaella Faggioni,Lorin Roskos

Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory hairy cell leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity.

2018

Denison J. Kuruvilla
Yen Lin Chia
Linda Santiago
Kemal Balic
Nai-Shun Yao
Robert J. Kreitman
Ira Pastan
Xia Li
Meina Liang
Chih-Ming Tseng
Raffaella Faggioni
Lorin Roskos

7060Background: Moxe is an immunotoxin targeting CD22 on B cells leading to cell death. The objectives of this analysis were to characterize the pharmacokinetics (PK) and evaluate the exposure-effi...

Keywords:

Drug
Oncology
Pathology
Immunogenicity
Disease burden
Moxetumomab pasudotox
Medicine
Refractory hairy cell leukemia
Internal medicine
Programmed cell death
Immunotoxin
CD22
Pharmacokinetics
Hairy cell leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations